Marcin F Osuchowski, Federico Aletti, Jean-Marc Cavaillon, Stefanie B Flohé, Evangelos J. Giamarellos-Bourboulis, Markus Huber-Lang, Borna Relja, Tomasz Skirecki, Andrea Szabó, Marc Maegele

Shock 2020 Oct;54(4):416-437
DOI 10.1097/SHK.0000000000001565


EJG-B: honoraria from AbbVie USA, Abbott CH, InflaRx GmbH, MSD Greece, XBiotech Inc. and Angelini Italy; independent educational grants from AbbVie, Abbott, Astellas Pharma Europe, AxisShield, bioMérieux Inc, InflaRx GmbH, and XBiotech Inc.; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis).

Keywords: Acute respiratory distress syndrome; animal models; clinical trials; immuno-modulation; pandemic; pneumonia